2022 Volume 30 Issue 1 Pages 45-49
Purpose: Omentectomy is a standard procedure to prevent advanced gastric cancer recurrence; however, there is no supporting evidence. We aimed to evaluate the benefit of omentectomy for patients with pT3 gastric cancer.
Methods: We reviewed 140 patients who underwent radical gastrectomy for pT3 gastric cancer between 2002 and 2016, and classified them into the omentum-preserved group (OPG) and the omentum-resected group (ORG). After propensity score matching, 23 patients in each group were included in the final analysis. Postoperative outcomes, overall survival, and relapse-free survival were compared between the two groups.
Results: The median follow-up was 5.14 years in OPG and 5.15 years in ORG. The incidence of postoperative complications of Clavien–Dindo grade III or more and postoperative hospital stay were not significantly different between the groups. The OPG and ORG had 5-year overall survival (OS) rates of 77.6% and 81.8% (P = 0.64) and relapse-free survival (RFS) rates of 95.0% and 72.7% (P = 0.04), respectively.
Conclusion: In pT3 gastric cancer, the OS and RFS rates were comparable between the two groups, which warrant further investigation in randomized clinical trials.
